Tani Mariko, Maebashi Kazunori, Araake Minako, Watabe Hiroomi
Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama, Japan.
Jpn J Antibiot. 2002 Dec;55(6):882-5.
The inhibitory activity of NM394, the active form of the prodrug prulifloxacin, against type II topoisomerase from Pseudomonas aeruginosa was compared with those of ciprofloxacin (CPFX), levofloxacin (LVFX) and gatifloxacin (GFLX). The 50% inhibitory concentrations (IC50S) of NM394 for supercoiling activity of DNA gyrase and the decatenation activity of topoisomerase IV were 1.21 and 21.1 micrograms/ml, respectively. The IC50 of NM394 was equal to that of CPFX and lower than those of LVFX and GFLX. The inhibitory activity of the four drugs for DNA gyrase was also corresponding to the antimicrobial activity of the drugs for P. aeruginosa PAO1. The IC50S of the drugs tested for the decatenation activity of topoisomerase IV were from 17.4 to 24.2 times higher than those for the supercoiling activities of DNA gyrase. These results show that DNA gyrase is more sensitive to quinolones than is topoisomerase IV and may be a primary target of quinolones in P. aeruginosa. We concluded that NM394 exerts the potent antimicrobial activity through its strong inhibitory activity for DNA gyrase.
将前体药物普卢利沙星的活性形式NM394对铜绿假单胞菌II型拓扑异构酶的抑制活性与环丙沙星(CPFX)、左氧氟沙星(LVFX)和加替沙星(GFLX)进行了比较。NM394对DNA回旋酶超螺旋活性和拓扑异构酶IV解连环活性的50%抑制浓度(IC50)分别为1.21和21.1微克/毫升。NM394的IC50与CPFX相当,低于LVFX和GFLX。这四种药物对DNA回旋酶的抑制活性也与它们对铜绿假单胞菌PAO1的抗菌活性相对应。所测试药物对拓扑异构酶IV解连环活性的IC50比对DNA回旋酶超螺旋活性的IC50高17.4至24.2倍。这些结果表明,DNA回旋酶对喹诺酮类药物比拓扑异构酶IV更敏感,可能是喹诺酮类药物在铜绿假单胞菌中的主要靶点。我们得出结论,NM394通过其对DNA回旋酶的强抑制活性发挥强大的抗菌活性。